Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,064 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
Arenillas L, Calvo X, Luño E, Senent L, Alonso E, Ramos F, Ardanaz MT, Pedro C, Tormo M, Marco V, Montoro J, Díez-Campelo M, Brunet S, Arrizabalaga B, Xicoy B, Andreu R, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L. Arenillas L, et al. Among authors: ferrer a. J Clin Oncol. 2016 Sep 20;34(27):3284-92. doi: 10.1200/JCO.2016.66.9705. Epub 2016 Jul 5. J Clin Oncol. 2016. PMID: 27382099
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L. Calvo X, et al. Among authors: ferrer a. Mod Pathol. 2016 Dec;29(12):1541-1551. doi: 10.1038/modpathol.2016.146. Epub 2016 Aug 26. Mod Pathol. 2016. PMID: 27562492 Free article.
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Blanco ML, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ferrer A, Sanz GF, Florensa L. Calvo X, et al. Among authors: ferrer a. Am J Hematol. 2017 Jul;92(7):614-621. doi: 10.1002/ajh.24732. Epub 2017 May 9. Am J Hematol. 2017. PMID: 28370234 Free article.
Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: from molecular profiling to flow cytometry.
Espinet B, Ferrer A, Bellosillo B, Nonell L, Salar A, Fernández-Rodríguez C, Puigdecanet E, Gimeno J, Garcia-Garcia M, Vela MC, Luño E, Collado R, Navarro JT, de la Banda E, Abrisqueta P, Arenillas L, Serrano C, Lloreta J, Miñana B, Cerutti A, Florensa L, Orfao A, Sanz F, Solé F, Dominguez-Sola D, Serrano S. Espinet B, et al. Among authors: ferrer a. Clin Cancer Res. 2014 Feb 15;20(4):1007-19. doi: 10.1158/1078-0432.CCR-13-1077. Epub 2013 Dec 18. Clin Cancer Res. 2014. PMID: 24352646 Free PMC article.
Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum.
Calvo X, Roman-Bravo D, Garcia-Gisbert N, Rodriguez-Sevilla JJ, Garcia-Avila S, Florensa L, Gibert J, Fernández-Rodríguez C, Salido M, Puiggros A, Espinet B, Colomo L, Bellosillo B, Ferrer A, Arenillas L. Calvo X, et al. Among authors: ferrer a. Blood Adv. 2022 Jul 12;6(13):3921-3931. doi: 10.1182/bloodadvances.2022007359. Blood Adv. 2022. PMID: 35709473 Free PMC article.
Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.
Calvo X, Garcia-Gisbert N, Parraga I, Gibert J, Florensa L, Andrade-Campos M, Merchan B, Garcia-Avila S, Montesdeoca S, Fernández-Rodríguez C, Salido M, Puiggros A, Espinet B, Colomo L, Roman-Bravo D, Bellosillo B, Ferrer A, Arenillas L. Calvo X, et al. Among authors: ferrer a. Blood Adv. 2020 Oct 27;4(20):5285-5296. doi: 10.1182/bloodadvances.2020002206. Blood Adv. 2020. PMID: 33108455 Free PMC article.
1,064 results